BBH - ETF AI Analysis
Top Page
VanEck Biotech ETF (BBH)
Rating:73Outperform
Price Target:―
Positive Factors
Focused Biotech Exposure
The fund is heavily invested in health care and biotechnology companies, giving investors targeted access to this specialized growth area.
Leading Large-Cap Holdings
Top positions like Amgen and Gilead Sciences have shown steady gains this year, helping support the ETF’s overall performance.
Moderate Expense Ratio
The fund’s expense ratio is relatively moderate for a specialized biotech ETF, which helps investors keep more of their returns over time.
Negative Factors
High Stock Concentration
A small number of holdings make up a large share of the portfolio, increasing the impact that any one company’s moves can have on the fund.
Several Weak Top Holdings
Some of the larger positions, such as Vertex, Regeneron, Alnylam, and Insmed, have shown weak performance this year, which can drag on returns.
Limited Diversification
With almost all assets in U.S. health care stocks, the ETF offers little protection if the biotech sector or U.S. market faces a downturn.
BBH vs. SPDR S&P 500 ETF (SPY)
AUM370.99M
RegionGlobal
Expense Ratio0.35%
Beta0.67
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield0.52%
Asset ClassEquity
Index TrackedMVIS US Listed Biotech 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,094
30 Day Avg. Volume7,056
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
222.23Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBH Summary
The VanEck Biotech ETF (BBH) tracks the MVIS US Listed Biotech 25 Index and focuses on U.S. biotechnology companies within the health care sector. It holds well-known names like Amgen and Gilead Sciences, along with smaller biotech firms working on new drugs, genetic research, and medical technologies. Someone might invest in BBH to seek long-term growth from medical breakthroughs and to get diversified exposure to many biotech companies in a single investment. However, biotech stocks can be very volatile, so the ETF’s price can swing sharply and may go up or down more than the overall market.
How much will it cost me?The VanEck Biotech ETF (BBH) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused ETF that targets biotechnology companies, which often require more active management to track this specialized market. It’s important to consider whether the potential growth in this niche sector aligns with your investment goals.
What would affect this ETF?The VanEck Biotech ETF (BBH) could benefit from advancements in biotechnology, such as breakthroughs in drug development and genetic research, as well as increased global demand for innovative health solutions. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding for biotech companies. Additionally, changes in interest rates could affect the financial performance of its top holdings like Gilead Sciences and Amgen.
BBH Top 10 Holdings
BBH is a pure biotech play, and its story right now is all about a few heavy hitters calling the shots. Gilead and Amgen sit in the driver’s seat, both rising and giving the fund a solid backbone of large, profitable drug makers. Vertex and Regeneron are also pulling their weight, adding steady to upbeat momentum from innovative pipelines. On the flip side, names like Natera and Alnylam have been lagging, acting as a bit of a brake. While the ETF is globally focused, its top holdings are largely U.S.-based biotech leaders.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Gilead Sciences | 17.04% | $61.98M | $175.40B | 31.42% | 78 Outperform | |
| Amgen | 16.69% | $60.68M | $189.47B | 11.32% | 77 Outperform | |
| Vertex Pharmaceuticals | 9.36% | $34.03M | $114.72B | -11.89% | 78 Outperform | |
| Regeneron | 7.67% | $27.90M | $78.66B | 10.67% | 78 Outperform | |
| Argenx Se | 3.96% | $14.40M | $42.59B | 10.45% | 79 Outperform | |
| Natera | 3.80% | $13.84M | $28.03B | 31.10% | 73 Outperform | |
| Alnylam Pharma | 3.60% | $13.11M | $41.75B | 24.21% | 60 Neutral | |
| Insmed | 3.48% | $12.66M | $30.76B | 80.77% | 43 Neutral | |
| IQVIA Holdings | 3.47% | $12.62M | $28.34B | -10.66% | 73 Outperform | |
| Biogen | 3.37% | $12.25M | $26.76B | 28.90% | 74 Outperform |
BBH Technical Analysis
Negative
―
Price Trends
194.44
Negative
191.04
Negative
176.57
Positive
Market Momentum
-2.40
Positive
34.80
Neutral
9.56
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 192.56, equal to the 50-day MA of 194.44, and equal to the 200-day MA of 176.57, indicating a neutral trend. The MACD of -2.40 indicates Positive momentum. The RSI at 34.80 is Neutral, neither overbought nor oversold. The STOCH value of 9.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BBH.
BBH Peer Comparison
Comparison Results
Performance Comparison
BBH
VanEck Biotech ETF
184.27
25.07
15.75%
CRBN
iShares MSCI ACWI Low Carbon Target ETF
―
―
―
BLOK
Amplify Transformational Data Sharing Etf
―
―
―
IVES
Dan IVES Wedbush AI Revolution ETF
―
―
―
BUG
Global X Cybersecurity Etf
―
―
―
CANC
Tema Oncology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents